NASDAQ: CSBRChampions Oncology Inc Stock
$7.92-0.05 (-0.63%)
Updated Apr 21, 2025
CSBR Price
$7.92
Fair Value Price
-$4.42
Market Cap
$109.51M
52 Week Low
$3.60
52 Week High
$11.99
P/E
16.85x
P/B
20.02x
P/S
2.57x
PEG
0.08x
Dividend Yield
N/A
Revenue
$58.59M
Earnings
$6.43M
Gross Margin
51.6%
Operating Margin
10.92%
Profit Margin
11%
Debt to Equity
4.6
Operating Cash Flow
-$1M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CSBR Overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CSBR's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CSBR
Ranked#13 of 462
Ranked#13 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CSBR news, forecast changes, insider trades & much more!
CSBR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CSBR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CSBR ($7.92) is overvalued by 279.18% relative to our estimate of its Fair Value price of -$4.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CSBR ($7.92) is not significantly undervalued (279.18%) relative to our estimate of its Fair Value price of -$4.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CSBR ($7.92) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CSBR due diligence checks available for Premium users.
Valuation
CSBR fair value
Fair Value of CSBR stock based on Discounted Cash Flow (DCF)
Price
$7.92
Fair Value
-$4.42
Undervalued by
279.18%
CSBR ($7.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CSBR ($7.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CSBR ($7.92) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CSBR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
16.85x
Industry
-184.27x
Market
27.14x
CSBR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CSBR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CSBR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
20.02x
Industry
4.04x
CSBR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CSBR price to earnings growth (PEG)
For valuing profitable companies with growth potential
CSBR is good value based... subscribe to Premium to read more.
PEG Value Valuation
CSBR's financial health
Profit margin
Revenue
$17.0M
Net Income
$4.5M
Profit Margin
26.4%
CSBR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CSBR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$30.6M
Liabilities
$25.2M
Debt to equity
4.6
CSBR's short-term liabilities ($19.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CSBR's short-term assets ($19.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CSBR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CSBR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$490.0k
Investing
-$42.0k
Financing
$0.0
CSBR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CSBR vs Biotech Stocks
Champions Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.